Search research articles
Contact Us
Filters
Showing results (91-100 of 106) with videos related to
Page
of 11
Sort By:
Oncotarget
|
March 24, 2016
A phase I study of indoximod in patients with advanced malignancies
Hatem H Soliman, Susan E Minton, Hyo Sook Han, et al.
Oncotarget
|
May 24, 2016
Phase I study of pemetrexed with sorafenib in advanced solid tumors
Andrew Poklepovic, Sarah Gordon, Danielle A Shafer, et al.
Blood Advances
|
August 14, 2020
Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects
Julie Kanter, Wally R Smith, Payal C Desai, et al.
JAMA
|
December 29, 2016
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial
Andrew L Himelstein, Jared C Foster, James L Khatcheressian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2
Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
American Journal of Clinical Oncology
|
July 16, 2019
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
Sarah W Gordon, William P McGuire, Danielle A Shafer, et al.
Cancer Chemotherapy and Pharmacology
|
February 22, 2012
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
Prithviraj Bose, Edward B Perkins, Connie Honeycut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms
Beata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 21, 2018
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
Victor Yazbeck, Danielle Shafer, Edward B Perkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Beata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 106) with videos related to
Sort By:
Page
of 11
Oncotarget
|
March 24, 2016
A phase I study of indoximod in patients with advanced malignancies
Hatem H Soliman, Susan E Minton, Hyo Sook Han, et al.
Oncotarget
|
May 24, 2016
Phase I study of pemetrexed with sorafenib in advanced solid tumors
Andrew Poklepovic, Sarah Gordon, Danielle A Shafer, et al.
Blood Advances
|
August 14, 2020
Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects
Julie Kanter, Wally R Smith, Payal C Desai, et al.
JAMA
|
December 29, 2016
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial
Andrew L Himelstein, Jared C Foster, James L Khatcheressian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 22, 2013
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2
Beata Holkova, Jeffrey G Supko, Matthew M Ames, et al.
American Journal of Clinical Oncology
|
July 16, 2019
Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma
Sarah W Gordon, William P McGuire, Danielle A Shafer, et al.
Cancer Chemotherapy and Pharmacology
|
February 22, 2012
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies
Prithviraj Bose, Edward B Perkins, Connie Honeycut, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms
Beata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
August 21, 2018
A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma
Victor Yazbeck, Danielle Shafer, Edward B Perkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 9, 2015
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
Beata Holkova, Adriana Zingone, Maciej Kmieciak, et al.
Page
of 11